consisting of:

a) a naturally-occurring amino acid sequence having at least 90% amino acid sequence identity to SEQ ID NO:1, and

b) a naturally-occurring amino acid sequence having at least 90% amino acid sequence identity to SEQ ID NO:2.

14. A purified antibody which specifically binds to a polypeptide of claim 1.

15. A purified agonist which specifically binds to and modulates the activity of a polypeptide of claim 1.

16. A purified antagonist which specifically binds to and modulates the activity of a polypeptide of claim 1.

17. A method for treating or preventing a neoplastic disorder, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 16.

18. A method for treating or preventing a reproductive disorder, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 16.

21. A polypeptide of claim 1, having the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2.

22. A composition comprising a polypeptide of claim 21 in conjunction with a suitable pharmaceutical carrier.

23. An isolated polynucleotide selected from the group consisting of:

a) a polynucleotide sequence of SEQ ID NO:3,

b) a polynucleotide sequence of SEQ ID NO:4,

c) a naturally-occurring polynucleotide sequence having at least 90% sequence identity to the sequence of SEQ ID NO:3,

d) a naturally-occurring polynucleotide sequence having at least 90% sequence identity to the sequence of SEQ ID NO:4, and

e) a polynucleotide sequence complementary to a), b), c) or d).

24. A method of detecting a target polynucleotide in a sample, said target polynucleotide having the sequence of a polynucleotide of claim 23, comprising

hybridizing the sample with a probe comprising at least 16 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and

detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

25. A method of claim 24, wherein the probe comprises at least 30 contiguous nucleotides.

26. A method of claim 24, wherein the probe comprises at least 60 contiguous nucleotides.

27. A composition comprising a polypeptide of claim 1 in conjunction with a suitable pharmaceutical carrier.

F2

28. A substantially purified polypeptide comprising a fragment of the polypeptide of claim 1, wherein said fragment consists of at least 15 contiguous amino acids of SEQ ID NO:1, and wherein said fragment binds specifically with an anti-PGAMP-1 antibody.

29. A composition comprising the polypeptide of claim 28 in conjunction with a suitable

pharmaceutical carrier.

30. A method of screening for a compound that specifically binds to the polypeptide of claim 21, said method comprising the steps of:

a) combining the polypeptide of claim 21 with at least one test compound under suitable conditions, and

b) detecting binding of the polypeptide of claim 21 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 21.

31. A method for producing an antibody that specifically binds to the polypeptide of claim 21, the method comprising:

a) inoculating a mammal with the polypeptide of claim 21 under conditions such that the mammal makes antibodies that bind specifically to the polypeptide of claim 21, and

b) isolating said antibodies from said mammal.

32. A method for determining whether a sample contains a polypeptide having the amino acid sequence of either SEQ ID NO:1 or SEQ ID NO:2, the method comprising:

a) contacting the antibody produced by the method of claim 31 with said sample, and

b) detecting specific binding of said antibody to said sample, wherein the presence of specific binding indicates the presence of a polypeptide having the amino acid sequence of either SEQ ID NO:1 or SEQ ID NO:2 in said sample.